Elron completes Elbit divestiture

Article

Israeli technology holding company Elron Electronic Industries this month completed the divestiture of its share of Elbit Medical Imaging to Europe Israel, an Israeli real estate investment firm. The divestiture has been complicated, however, by the

Israeli technology holding company Elron Electronic Industries this month completed the divestiture of its share of Elbit Medical Imaging to Europe Israel, an Israeli real estate investment firm. The divestiture has been complicated, however, by the filing of litigation by two of Elbit’s minority shareholders. The shareholders are claiming that the terms of the sale are slanted in favor of Elron.

Elron announced on May 4 that it had completed the deal to sell its 37% stake in Elbit for $145 million. Under terms of the agreement, Europe Israel has the right to request that Elron invest in a new image-guided therapy joint venture. Elron agreed to the condition in order to win the Israeli government’s approval of the sale (SCAN 4/14/98).

Elbit’s future, and that of its Elscint subsidiary, is now uncertain. Elscint still maintains some medical imaging manufacturing operations, but company observers believe that Europe Israel could be more interested in gaining access to the company’s cash than its technology. Concurrent with the closing of the acquisition, Europe Israel replaced Elscint’s board with directors who, for the most part, represent Israel’s real estate and hotel industry.

In the minority shareholder litigation, two Israeli insurance companies that together own 4.1% of Elbit filed suit claiming that the Europe Israel deal favored Elron over minority shareholders. The plaintiffs have asked an Israeli court for class-action status, and may request that Europe Israel buy out their Elbit stake under the same terms with which it acquired Elron’s position, according to a source close to Elbit.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.